0001683168-19-001391.txt : 20190507 0001683168-19-001391.hdr.sgml : 20190507 20190507172526 ACCESSION NUMBER: 0001683168-19-001391 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190507 DATE AS OF CHANGE: 20190507 EFFECTIVENESS DATE: 20190507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-339029 FILM NUMBER: 19804267 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 D 1 primary_doc.xml X0708 D LIVE 0000908259 MATEON THERAPEUTICS INC 701 GATEWAY BLVD. SUITE 210 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 650-635-7000 DELAWARE OXiGENE, Inc. OXIGENE INC Corporation true Vuong Trieu 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer Director William Schwieterman 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Director Matthew Loar 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Executive Officer Fatih Uckun 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer Chulho Park 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer Biotechnology Decline to Disclose 06b false 2019-04-22 false true true Securities issued pursuant to the Agreement and Plan of Merger dated April 17, 2019, among the Issuer and Oncotelic, Inc. 0 John Calcagnini 1406341 Stout Risius Ross Advisors, LLC 127302 10100 SANTA MONICA BLVD., SUITE 1050 LOS ANGELES CA CALIFORNIA 90067 CA CALIFORNIA NC NORTH CAROLINA MN MINNESOTA PA PENNSYLVANIA false 27000000 27000000 0 Shares of the Issuer's Common Stock and Series A Convertible Preferred Stock issued to stockholders of Oncotelic, Inc. in connection with merger. false 26 545000 0 0 false MATEON THERAPEUTICS INC /s/ Vuong Trieu Vuong Trieu CEO 2019-05-07